Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes

Conclusion: Dulaglutide is a once-weekly GLP-1 RA approved for the treatment of T2DM that has shown similar efficacy to other agents in this class. Keywords: GLP-1 RA, glucagon-like peptide-1 receptor agonist, incretin mimetic, type 2 diabetes mellitus therapy
Source: Core Evidence - Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research